Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong · Delayed Price · Currency is HKD

14.08

-0.21 (-1.47%)

Jun 18, 2026, 11:22 AM HKT

-11.11% (1Y)

Market Cap	3.21B +28.8%
Revenue (ttm)	897.99M +408.2%
Net Income	349.92M
EPS	1.56
Shares Out	224.57M
PE Ratio	9.14
Forward PE	14.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,200
Open	14.41
Previous Close	14.29
Day's Range	14.08 - 14.60
52-Week Range	14.02 - 36.50
Beta	1.42
Analysts	Buy
Price Target	33.00 (+134.38%)
Earnings Date	Mar 27, 2026

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis unde... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 337

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2509

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2509 stock is "Buy." The 12-month stock price target is $33.00, which is an increase of 134.38% from the latest price.

Price Target

$33.00

(134.38% upside)

Analyst Consensus: Buy

Stock Forecasts